Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Ezekowitz

Showing results (31-40 of 49) with videos related to

Pageof 5
Sort By:
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 22, 2016
Major Gastrointestinal Bleeding Often Is Caused by Occult Malignancy in Patients Receiving Warfarin or Dabigatran to Prevent Stroke and Systemic Embolism From Atrial FibrillationKathryn F Flack, Jay Desai, Jennifer M Kolb, et al.
Medrxiv : the Preprint Server for Health Sciences|March 30, 2023
Overestimation of anticoagulant benefit in patients with atrial fibrillation and low life expectancy: evidence from 12 randomized trialsSachin J Shah, Carl van Walraven, Sun Young Jeon, et al.
Circulation|May 7, 2013
Response to letters regarding article, “Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Randomized Trial”Jeff S Healey, John Eikelboom, Sean Yang, et al.
Circulation|June 16, 2012
Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trialJeff S Healey, John Eikelboom, James Douketis, et al.
Pharmacogenomics|August 5, 2016
Genetic determinants of warfarin maintenance dose and time in therapeutic treatment range: a RE-LY genomics substudyNiclas Eriksson, Lars Wallentin, Lars Berglund, et al.
Circulation. Arrhythmia and Electrophysiology|May 2, 2022
Drug Interactions Affecting Antiarrhythmic Drug UsePhilip L Mar, Piotr Horbal, Mina K Chung, et al.
Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology|March 25, 2017
Short-term dabigatran interruption before cardiac rhythm device implantation: multi-centre experience from the RE-LY trialVidal Essebag, Riccardo Proietti, David H Birnie, et al.
Journal of Cardiac Failure|April 22, 2004
The Warfarin and Antiplatelet Therapy in Heart Failure trial (WATCH): rationale, design, and baseline patient characteristicsBarry M Massie, William F Krol, Susan E Ammon, et al.
Circulation|March 18, 2009
Randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure: the Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) trialBarry M Massie, Joseph F Collins, Susan E Ammon, et al.
Journal of the American Heart Association|August 27, 2024
Residual Stroke Risk Among Patients With Atrial Fibrillation Prescribed Oral Anticoagulants: A Patient-Level Meta-Analysis From COMBINE AFLinda S Johnson, Alexander P Benz, Ashkan Shoamanesh, et al.
Pageof 5

Showing results (31-40 of 49) with videos related to

Sort By:
Pageof 5
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 22, 2016
Major Gastrointestinal Bleeding Often Is Caused by Occult Malignancy in Patients Receiving Warfarin or Dabigatran to Prevent Stroke and Systemic Embolism From Atrial FibrillationKathryn F Flack, Jay Desai, Jennifer M Kolb, et al.
Medrxiv : the Preprint Server for Health Sciences|March 30, 2023
Overestimation of anticoagulant benefit in patients with atrial fibrillation and low life expectancy: evidence from 12 randomized trialsSachin J Shah, Carl van Walraven, Sun Young Jeon, et al.
Circulation|May 7, 2013
Response to letters regarding article, “Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Randomized Trial”Jeff S Healey, John Eikelboom, Sean Yang, et al.
Circulation|June 16, 2012
Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trialJeff S Healey, John Eikelboom, James Douketis, et al.
Pharmacogenomics|August 5, 2016
Genetic determinants of warfarin maintenance dose and time in therapeutic treatment range: a RE-LY genomics substudyNiclas Eriksson, Lars Wallentin, Lars Berglund, et al.
Circulation. Arrhythmia and Electrophysiology|May 2, 2022
Drug Interactions Affecting Antiarrhythmic Drug UsePhilip L Mar, Piotr Horbal, Mina K Chung, et al.
Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology|March 25, 2017
Short-term dabigatran interruption before cardiac rhythm device implantation: multi-centre experience from the RE-LY trialVidal Essebag, Riccardo Proietti, David H Birnie, et al.
Journal of Cardiac Failure|April 22, 2004
The Warfarin and Antiplatelet Therapy in Heart Failure trial (WATCH): rationale, design, and baseline patient characteristicsBarry M Massie, William F Krol, Susan E Ammon, et al.
Circulation|March 18, 2009
Randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure: the Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) trialBarry M Massie, Joseph F Collins, Susan E Ammon, et al.
Journal of the American Heart Association|August 27, 2024
Residual Stroke Risk Among Patients With Atrial Fibrillation Prescribed Oral Anticoagulants: A Patient-Level Meta-Analysis From COMBINE AFLinda S Johnson, Alexander P Benz, Ashkan Shoamanesh, et al.
Pageof 5